Preclinical data show that iadademstat synergizes with standard therapies and enhances the effectiveness of BCL2 inhibition in vitro [96], and clinical trials are investigating its combination with AZA/VEN in AML (NCT06357182 and NCT06514261). The gene discussed is BCL2; the disease is acute myeloid leukemia.